MedPath
FDA Approval

Piperacillin and Tazobactam

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
April 2, 2021
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Piperacillin(3 g in 15 mL)
Tazobactam(0.375 g in 15 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Haupt Pharma Latina S.r.l.

Fresenius Kabi USA, LLC

338690598

Products3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Piperacillin and Tazobactam

Product Details

NDC Product Code
63323-983
Application Number
ANDA203719
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
January 23, 2020
Code: M98T69Q7HPClass: ACTIMQuantity: 3 g in 15 mL
Code: UXA545ABTTClass: ACTIMQuantity: 0.375 g in 15 mL

Piperacillin and Tazobactam

Product Details

NDC Product Code
63323-981
Application Number
ANDA203719
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
January 23, 2020
Code: M98T69Q7HPClass: ACTIMQuantity: 2 g in 10 mL
Code: UXA545ABTTClass: ACTIMQuantity: 0.25 g in 10 mL

Piperacillin and Tazobactam

Product Details

NDC Product Code
63323-982
Application Number
ANDA203719
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
January 23, 2020
Code: M98T69Q7HPClass: ACTIMQuantity: 4 g in 20 mL
Code: UXA545ABTTClass: ACTIMQuantity: 0.5 g in 20 mL
© Copyright 2025. All Rights Reserved by MedPath